Comparison of Two Diagnostic Assays for Anti-Laminin 332 Mucous Membrane Pemphigoid

Stephanie Goletz, Federica Giurdanella, Maike M. Holtsche, Miranda Nijenhuis, Barbara Horvath, Gilles F.H. Diercks, Detlef Zillikens, Takashi Hashimoto, Enno Schmidt*, Hendri H. Pas

*Corresponding author for this work
2 Citations (Scopus)

Abstract

Anti-laminin 332 mucous membrane pemphigoid (MMP) is an autoimmune blistering disease characterized by predominant mucosal lesions and autoantibodies against laminin 332. The exact diagnosis of anti-laminin 332 MMP is important since nearly 30% of patients develop solid cancers. This study compared two independently developed diagnostic indirect immunofluorescence (IF) tests based on recombinant laminin 332 expressed in HEK239 cells (biochip mosaic assay) and the migration trails of cultured keratinocytes rich in laminin 332 (footprint assay). The sera of 54 anti-laminin 332 MMP, 35 non-anti-laminin 332 MMP, and 30 pemphigus vulgaris patients as well as 20 healthy blood donors were analyzed blindly and independently. Fifty-two of 54 and 54/54 anti-laminin 332 MMP sera were positive in the biochip mosaic and the footprint assay, respectively. In the 35 non-anti-laminin 332 MMP sera, 3 were positive in both tests and 4 others showed weak reactivity in the footprint assay. In conclusion, both assays are easy to perform, highly sensitive, and specific, which will further facilitate the diagnosis of anti-laminin 332 MMP.

Original languageEnglish
Article number773720
JournalFrontiers in Immunology
Volume12
ISSN1664-3224
DOIs
Publication statusPublished - 25.11.2021

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)
  • Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

  • 2.21-05 Immunology
  • 2.22-19 Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  • SDG 3 - Good Health and Well-being

Access to Document

Other files and links

  • EXC 2167: Precision Medicine in Chronic Inflammation (PMI)

    Schreiber, S. (Speaker, Coordinator), Baines, J. F. (Project Staff), Bosch, T. C. G. (Project Staff), Buyx, A. (Project Staff), Erdmann, J. (Project Staff), Franke, A. (Project Staff), Huber, R. (Project Staff), Klein, C. (Project Staff), Köhl, J. (Project Staff), König, I. R. (Project Staff), Lange, C. (Project Staff), Laudes, M. (Project Staff), Lieb, W. (Project Staff), Ludwig, R. (Project Staff), Nebel, A. (Project Staff), Niemann, S. (Project Staff), Rabe, K. F. (Project Staff), Riemekasten, G. (Project Staff), Rose-John, S. (Project Staff), Rosenstiel, P. C. (Project Staff), Schulenburg, H. (Project Staff), Schwarz, K. (Project Staff), Traulsen, A. (Project Staff), Weidinger, S. (Project Staff) & Zillikens, D. (Project Staff)

    01.01.19 → …

    Project: DFG Projects › DFG Cluster of Excellence

  • CRU 303: Pemphigoid Diseases - Molecular Pathways and their Therapeutic Potential

    Sadik, C. (Speaker, Coordinator), Zillikens, D. (Speaker, Coordinator), Ibrahim, S. (Principal Investigator (PI)), Baines, J. F. (Principal Investigator (PI)), Schmidt, E. (Principal Investigator (PI)), Köhl, J. (Principal Investigator (PI)), Ehlers, M. (Principal Investigator (PI)), Hirose, M. (Principal Investigator (PI)), König, P. (Principal Investigator (PI)), Ludwig, R. (Principal Investigator (PI)), Manz, R. (Principal Investigator (PI)), Schwaninger, M. (Principal Investigator (PI)), Beek, N. (Principal Investigator (PI)), Erdmann, J. (Principal Investigator (PI)), König, I. R. (Principal Investigator (PI)), Verschoor, A. (Principal Investigator (PI)), Karsten, C. (Principal Investigator (PI)), Bieber, K. (Principal Investigator (PI)) & Busch, H. S. (Principal Investigator (PI))

    01.04.15 → 31.12.23

    Project: DFG Projects › DFG Joint Research: Research Units/Clinical Research Units

Cite this